Natural killer cells impede the engraftment of cardiomyocytes derived from induced pluripotent stem cells in syngeneic mouse model

Yuki Nakamura1, Shigeru Miyagawa1, Shohei Yoshida2, Shigemi Sasawatari2, Toshihiko Toyofuku2, Koichi Toda1 & Yoshiaki Sawa1

Transplantation of cardiomyocytes derived from induced pluripotent stem cell (iPSC-CMs) is a promising approach for increasing functional CMs during end-stage heart failure. Although major histocompatibility complex (MHC) class I matching between donor cells and recipient could reduce acquired immune rejection, innate immune responses may have negative effects on transplanted iPSC-CMs. Here, we demonstrated that natural killer cells (NKCs) infiltrated in iPSC-CM transplants even in a syngeneic mouse model. The depletion of NKCs using an anti-NKC antibody rescued transplanted iPSC-CMs, suggesting that iPSC-CMs activated NKC-mediated innate immunity. Surprisingly, iPSC-CMs lost inhibitory MHCs but not activating ligands for NKCs. Re-expression of MHC class I induced by IFN-γ as well as suppression of activating ligands by an antibody rescued the transplanted iPSC-CMs. Thus, NKCs impede the engraftment of transplanted iPSC-CMs because of lost MHC class I, and our results provide a basis for an approach to improve iPSC-CM engraftment.

End-stage heart failure is generally characterized by an insufficient number of functional cardiomyocytes (CMs). Although several clinical efforts involving pharmacological drugs and mechanical devices have been applied for treating end-stage heart failure, the beneficial effects of these maneuvers proved to be limited. Thus, transplanting CMs derived from induced pluripotent stem cells (iPSC-CMs) is a promising approach for end-stage heart failure because it can increase the number of functional CMs. Indeed, previous studies have demonstrated the beneficial effects of transplanted iPSC-CMs on the cardiac function of ischemic hearts in a mouse model and in a pig model.

For successful cell transplantation, transplanted cells should escape from immune rejection, which mainly occur through major histocompatibility complex (MHC)-mediated acquired immune responses. We have reported that acquired immune responses to transplanted iPSC-CMs in primates decreased dramatically in the MHC class I-matched model compared with the MHC class I-unmatched model. However, previous studies suggested that different immune responses such as with the innate immune system involving natural killer cells (NKCs) may have deleterious effects on transplanted cells even in MHC-matched model.

NKCs express inhibitory receptors for MHC class I molecules on target cells. MHC class I molecules, which are expressed on most cells, play a central role in inhibiting NKC-dependent lysis. Therefore, MHC class I-negative cells are lysed by NKCs through the "missing-self response". NKCs also express activating receptors such as CD226 and natural killer group 2D (NKG2D). The balance of activating and inhibitory signals determines NKC activation against target cells.

In this study, we aimed to investigate the innate immune response against transplanted syngeneic mouse iPSC-CMs (miPSC-CM) after in vivo transplantation. Histological analysis in syngeneic model showed large...
amounts of NKCs infiltrating in the transplants compared with other innate immune cells and T cells, suggesting that NKC-mediated innate immune responses may occur in the transplants. Surprisingly, miPSC-CMs lost inhibitory ligands such as MHC class I molecules, but not activating ligands for CD226 and NKG2D on their surfaces. These results indicated that NKCs play an important role in the survival of transplanted miPSC-CMs through innate immune responses.

**Results**

**Cardiomyogenic differentiation of mouse miPSCs and elimination of undifferentiated miPSCs.** We used the miPSC line, 959A2-1, generated from C57BL/6 mouse embryonic fibroblasts, which were then treated with neomycin to establish an miPSC line that stably expressed DsRed and luciferase (DsRed-Luciferase-miPSC), as previously described. Cardiomyogenic differentiation of DsRed-Luciferase-miPSCs was induced using a slightly modified culture protocol, according to the schema shown in Fig. 1A. On day 6, cells spontaneously started regular beating and well-beating embryoid bodies of miPSC-CMs were observed on day 16 (Fig. 1B and Movie S1). After 16 days of differentiation, immunohistochemical staining of the beating cell clusters demonstrated that troponin T were labeled in the cytoplasm, indicating the formation of well-aligned sarcomere structures (Fig. 1C). Flow cytometry showed that 66.7 ± 10.6% of the cells were positive for troponin T (Fig. 1D), whereas 3–7% of the cells were positive for stage-specific embryonic antigen (SSEA)-1, one of the major cell-surface markers of undifferentiated miPSCs, as assessed by flow cytometry (Fig. 1E). To eliminate undifferentiated miPSCs, SSEA-1-negative miPSC-CMs were isolated with an SH800Z cell sorter (Sony). After sorting, SSEA-1-positive cells were not detected by flow cytometry (Fig. 1F). The percentage of Troponin T-positive cells was maintained, even after sorting (Fig. S1A). Among the miPSC lines, miPSC-CMs representing 60–70% of Troponin T-positive cells were used in the subsequent experiments similar to a previous study. The SSEA-1-negative miPSC-CMs were seeded in temperature-responsive dishes, and the miPSC-CM sheets (which showed self-beating; Movie S2) were collected at room temperature just before transplantation.

**High-level secretion of chemokines from miPSC-CMs.** Immunoassays performed using fluorescently labeled microspheres demonstrated that the miPSC-CM sheet culture supernatant contained high concentrations of several chemokines, such as stromal cell-derived factor 1α (SDF-1α/CXCL12) and monocyte chemotactic protein-1 (MCP-1/CCL2) (Fig. S1B), which are known to affect NKC activity. The iPSC-CM sheet culture supernatant contained low amounts of CCL19, CXCL10, and CXCL11; CXC3L1 and CCL21 were not investigated. A NKC migration assay using the miPSC-CM sheet culture supernatant demonstrated that culture supernatants significantly chemoattracted NKCs, whereas the administration of blocking antibodies against SDF-1α/CXCL12 and MCP-1/CCL2 significantly reduced NKC chemotaxis (Fig. S1C).

**NKCs were recruited into miPSC-CM transplants in a syngeneic model.** To investigate the immunological rejection of transplanted miPSC-CMs in a syngeneic model, we subcutaneously transplanted miPSC-CM sheets into the back of C57BL/6 mice and histologically assessed the infiltration of inflammatory cells into or near the transplants at 4 days post-transplantation. Staining was confirmed using mouse spleens as a positive control (Fig. S2A). Regarding adaptive immune responses, no significant infiltration of CD3-positive lymphocytes was observed in syngeneic model (Fig. 1G), while drastic adaptive immune responses with CD3-positive cells were used in the subsequent experiments. The SSEA-1-negative miPSC-CMs were seeded in temperature-responsive dishes, and the miPSC-CM sheets (which showed self-beating; Movie S2) were collected at room temperature just before transplantation.

Recruited NKCs deteriorated miPSC-CMs. To determine whether recruited NKCs deteriorate miPSC-CMs, we transplanted miPSC-CMs into mice lacking NKCs by using anti-NK1.1 antibody. Flow cytometry confirmed that administration of an anti-NK1.1 antibody successfully depleted NKCs in the spleens of treated mice (Fig. S3A). The miPSC-derived cardiac tissue sheets were transplanted subcutaneously into control (syngeneic model; n = 6) and anti-NK1.1 antibody-treated C57BL/6 mice (NK-depleted syngeneic model; n = 6). Quantitative bioluminescence imaging (BLI) demonstrated that the luminescence intensity of miPSC-CMs in the NK-depleted syngeneic mice at post-transplantation day 7 was significantly higher than those in control mice (68.9 ± 25.0% vs. 33.7 ± 17.7%, p < 0.05) (Fig. 2A,B). We also observed more surviving DsRed-positive and Troponin T-positive iPSC-CMs at post-transplantation day 7 in NK-depleted mice than in control mice (Fig. S3B). Moreover, the apoptosis index, which was calculated by dividing the number of Annexin V-positive cells by the total number of cells in each transplanted sheet, was significantly higher in control mice vs. NK-depleted mice (22.2 ± 2.9% vs. 8.1 ± 3.8%, p < 0.05) (Fig. 2C,D). These results indicated that recruited NKCs impeded the engraftment of miPSC-CM transplants in the syngeneic transplantation model.

In the transplants, multifocal infiltration of CD335-positive NKCs in the grafts was histologically observed with the control model. Only slight NKC infiltration was observed around the grafts with the NK-depleted model (Fig. 2E). Additionally, a functional marker for NKC activity, CD107a-positive cells in and around the grafts were observed more with the control model than in the NK-depleted model (Fig. 2F). Although the percentage of CD335-positive NKCs in the spleen was not significantly higher in control mice compared with mice without miPSC-CM transplantation (Fig. 2G), the percentage of CD107a-positive NKCs in control mice was significantly higher than that in mice without miPSC-CM transplantation (37.4 ± 3.5% vs. 7.2 ± 2.1%, p < 0.05).
Figure 1. Cardiomyogenic differentiation of murine iPSCs, elimination of undifferentiated iPSCs, and innate immune responses after transplantation of syngeneic iPSC-CMs in vivo. (A) CM-differentiation protocol. (B) Embryoid body of iPSC-CMs at day 16. Scale bar, 100 μm. (C) iPSC-CMs at day 16, stained with an antitroponin T antibody (Alexa Flour 488), an anti-phalloidin antibody (Alexa Flour 555), and 4',6-diamidino-2-phenylindole (DAPI). Scale bar, 50 μm. (D) Flow cytometry data for iPSC-CMs at day 16, stained with antitroponin T antibodies or an isotype-matched control. (E) Flow cytometry data for undifferentiated iPSCs at day 0 and (F) iPSC-CMs before and after cell sorting at day 16, stained with SSEA-1 antibodies or the isotype control. (G) Subcutaneous tissue 4 days after iPSC-CM syngeneic transplantation stained with anti-CD3 (Alexa Flour 488), anti-CD68 (Alexa Flour 488), anti-myeloperoxidase (Alexa Flour 647) and anti-CD335 (Alexa Flour 555) antibodies, and DAPI. Scale bars: 50 μm.
Figure 2. Engraftment of transplanted iPSC-CMs in subcutaneous tissue and activated NKC infiltration into transplants containing iPSC-CMs in an NKC-depleted syngeneic transplantation model. (A) Engraftment of transplanted iPSC-CMs was analyzed by BLI in an NKC-depleted model. Representative serial images of the BLI study in one NKC-depleted and one control syngeneic mouse. (B) The relative quantities of transplanted iPSC-CMs were compared with those at 1 day after transplantation and expressed as the mean ± SD (n = 6, respectively). *p < 0.05. (C) Annexin V staining of harvested subcutaneous tissue containing iPSC-CM grafts 7 days after transplantation. Scale bars: 50 μm. (D) Semi-quantitative scoring (apoptosis index) calculated by dividing the number of Annexin V-positive cells by the total number of cells in the transplanted sheet 7 days after transplantation. The results are shown as the mean ± SD, *p < 0.05. (E) Staining of subcutaneous tissue with DAPI and an anti-CD335 antibody (Alexa Flour 555) at 7 days post-iPSC-CM transplantation in an NKC-depleted model. Scale bars: 50 μm. (F) Staining of subcutaneous tissue with DAPI and an anti-CD107a antibody (Alexa Flour 488) at 7 days post-iPSC-CM transplantation in an NKC-depleted model. Scale bars: 50 μm.
Percentage of CD335-positive NKC s in splenocytes harvested from a C57BL/6 mouse without transplantation and a C57BL/6 mouse at 7 days post-transplantation, with or without NKC depletion and expressed as the mean ± SD (n = 4, respectively). \( * p < 0.05 \). (H) Flow cytometric detection of CD335 and CD107a expression on splenocytes harvested from C57BL/6 mice without transplantation and C57BL/6 mice at 7 days post-transplantation, with or without NKC depletion. (I) Percentage of CD107a-positive NKC s in CD335-positive NKC s present in splenocytes isolated from a C57BL/6 mouse without transplantation and a C57BL/6 mouse at 7 days post-transplantation without NKC depletion; expressed as means ± SD (n = 6, respectively); \( * p < 0.05 \). (J) Flow cytometric detection of CD335 and Granzyme B on splenocytes harvested from a C57BL/6 mouse without transplantation and from a C57BL/6 mouse at 7 days post-transplantation, with or without NKC depletion. (K) Percentage of Granzyme B-positive NKC s in CD335-positive NKC s present in splenocytes isolated from a C57BL/6 mouse without transplantation and a C57BL/6 mouse at 7 days post-transplantation without NKC depletion; expressed as means ± SD (n = 6, respectively); \( * p < 0.05 \). BLI; bioluminescence imaging.

(See Fig. 2H,I). Additionally, the percentage of NKC s positive for Granzyme B was significantly higher in control mice than in mice without miPSC-CM transplantation (62.9 ± 3.1 vs. 31.6 ± 17.1%, \( p < 0.05 \)) (Fig. 2J,K). These results indicated that recruited NKC s were activated after the transplants of miPSC-CMs.

Reduced expression of MHC class I molecules and the existence of NKC-activating ligands on miPSC-CMs. To determine how NKC s were recruited into miPSC-CM transplants, we investigated the expression of NKC ligands on miPSC-CMs using flow cytometry. Regarding inhibitory ligands of NKC s, such as MHC class I, flow cytometry demonstrated that classical MHC class I expression on miPSC-CMs was significantly lower than that on native splenocytes derived from C57BL/6 mice (splenocytes vs. miPSC-CMs; H2Db, 98.9 ± 0.6% vs. 2.1 ± 0.6%; H2Kb, 96.4 ± 3.3% vs. 0.7 ± 0.4%; \( p < 0.05 \)) (Fig. 3A,B). Lower expression of Q2 was also detected on miPSC-CMs, compared with native splenocytes (splenocytes vs. miPSC-CMs; Q2, 38.6 ± 22.0% vs. 0.3 ± 0.2%; \( p < 0.05 \)) (Fig. 3A,B). Regarding activating ligands of NKC s, we found that CD112 and CD155 (which are ligands of the activating receptor CD226) were expressed on miPSC-CMs (CD112, 45.4 ± 18.2%; CD155, 29.1 ± 5.0%). RAE-1, which is an NKGD2 ligand, was expressed at low levels on miPSC-CMs (Figs 3C and S4). These results indicated that preferential expression of activating ligands for NKC s were expressed on miPSC-CMs.

NKC-mediated immune responses were determined by the expression pattern of surface ligands on miPSC-CMs. To determine whether NKC-mediated immune responses were induced by NKC-ligand expression on miPSC-CMs, the cytotoxicity of miPSC-CMs incubated with purified NKC s from C57BL/6 mice was examined by performing lactate dehydrogenase (LDH)-release assays and calcein AM (CAM) assays. When miPSC-CMs were incubated with IFN-\( \gamma \), the expression of classical MHC class I on miPSC-CMs was upregulated significantly, compared with untreated miPSC-CMs. In contrast, the expression of non-classical MHC class I on miPSC-CMs was not upregulated by IFN-\( \gamma \) treatment (Fig. 3B). MHC class II expression on miPSC-CMs was also upregulated by IFN-\( \gamma \) treatment, compared with untreated miPSC-CMs (Fig. 3D). Additionally, the expression of CIITA and NLRC5, which are key transcriptional activators of MHC class I and class II in miPSC-CMs, was significantly upregulated by IFN-\( \gamma \) treatment (Fig. 3E). Flow cytometry showed that 96.1 ± 2.6% of the cultured NKC s extracted from C57BL/6 mouse spleens were positive for NK1.1 and negative for CD3 (Fig. 3F). Among these purified NKC s, 37.6% were positive for CD226 and 82.4% were positive for NKGD2 (Fig. 3G). After co-culturing NKC s and miPSC-CMs with or without IFN-\( \gamma \) treatment, the expression of classical MHC class I significantly decreased the release of LDH in miPSC-CMs (Fig. 4A, and S5A). This treatment significantly increased the cell viability in miPSC-CMs (Figs 4B,C and S5E,F) and decreased levels of Granzyme B (Fig. 4D). These results indicated that the loss of classical MHC class I in miPSC-CMs augmented NKC-mediated toxicity to miPSC-CMs.

The administration of blocking antibodies against CD226 or NKGD2 significantly decreased LDH release (Figs 4A and S5C,D). These antibodies also increased the viability of miPSC-CMs, as determined in CAM assays (Figs 4B,C and S5E,F) and decreased levels of Granzyme B (Fig. 4D). These results indicated that activating NKC ligands also augmented NKC-mediated immune responses. Together, these data suggest that NKC-mediated immune responses were induced by both NKC ligand expression and the loss of classical MHC class I in miPSC-CMs.

Uppregation of MHC-class I and blocking CD226 and NKGD2 reduced NKC infiltration into transplants and miPSC-CM necrosis. Finally, we investigated whether NKC-related responses after miPSC-CM transplantation could be suppressed by inducing MHC class I on miPSC-CMs and blocking pathway activation via CD226 and NKGD2. The miPSC-CM sheets were generated in the presence or absence of IFN-\( \gamma \) treatment. Both types of miPSC-CM sheets were transplanted subcutaneously into C57BL/6 mice, which were treated with or without a cocktail of blocking antibodies against CD226 and NKGD2 (MHC- control group, MHC- control group, MHC- Ab group, and MHC+ Ab group; n = 6 in each group). Immunohistochemistry demonstrated that the number of NKC s infiltrating the transplants was significantly suppressed by MHC class I upregulation by IFN-\( \gamma \) or by blocking activation pathway via CD226 and NKGD2 (MHC- control group, MHC- control group, MHC- Ab group, and MHC+ Ab group values: 235 ± 33 cells/mm\(^2\), 127 ± 15 cells/mm\(^2\), 84 ± 22 cells/mm\(^2\), and 36 ± 21 cells/mm\(^2\), respectively) (Fig. 5A,B). In addition, the apoptosis index in the transplants was significantly reduced by these two treatments (MHC- control group vs. MHC+ control group, 31.6 ± 2.4% and 18.6 ± 3.9%; and MHC- Ab group vs. MHC+ Ab group, 13.5 ± 7.3% and 6.2 ± 1.6%, respectively, \( p < 0.05 \)).
Figure 3. Expression analysis of NKC ligands on iPSC-CMs with or without IFN-γ treatment and expression of NKC-activating receptors on purified NKCs before coculture. (A) Flow cytometric detection of MHC class I molecule expression on C57BL/6 splenocytes using antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. (B) Flow cytometric detection of MHC class I molecule expression on iPSC-CMs with or without IFN-γ treatment. The iPSC-CMs were stained with antibodies against H2Db, H2Kb, Qa1-b, and Qa2, or isotype-matched control antibodies. (C) Flow cytometric detection of NKC-activating ligands on iPSC-CMs at day 16. The iPSC-CMs were stained with antibodies against MULT1, H-60, RAE-1, CD112, and CD155, or isotype-matched control antibodies. (D) Flow cytometric detection of MHC class II molecules on iPSC-CMs with or without IFN-γ treatment, stained with anti-I-A/I-E, CD40, CD80, and CD86 antibodies or isotype-matched control antibodies. (E) mRNA expression of CIITA and NLRC5 in iPSC-CMs with or without IFN-γ treatment, as measured by real-time PCR. The results are expressed relative to those of C57BL/6 splenocytes as means ± SD (n = 3, respectively); *p < 0.05. (F) Flow cytometric detection
of NK.1 and CD3 expression on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against NK.1 and CD3, or isotype-matched control antibodies. (G) Flow cytometric detection of NKC-activating receptors on cultured NKCs purified from C57BL/6 splenocytes, stained with antibodies against CD226 and NKG2D, or isotype-matched control antibodies.

respectively) (Fig. 5C,D). Therefore, MHC class I expression on miPSC-CMs and blocking activating pathways may improve the engraftment of miPSC-CMs after transplantation.

Discussion

In this study, remarkable NK infiltration into miPSC-CM transplants and systemic NK activation were observed after transplantation of miPSC-CMs in MHC-matched mice. Administering an anti-NK.1 antibody to eliminate endogenous NKCs significantly increased the numbers of engrafted miPSC-CMs in MHC-matched mice. Thus, NKC-related innate immune responses impeded the engraftment of miPSC-CMs. In agreement with this finding, miPSC-CMs lost cell-surface expression of MHC class I, which is required for MHC-dependent NKC inhibition.

Previous findings demonstrated that differentiated iPSCs, such as retinal pigment epithelial cells and vascular endothelial cells, showed similar levels of MHC class I expression compared with their native cells. Consequently, in vitro-differentiated cells acquired resistance against autologous NKCs. It is thus quite important to determine how miPSC-CMs lose MHC class I expression. Constitutive and induced transcription of the MHC-I and MHC-II genes is mediated by a set of conserved regulatory elements in their promoters and interacting transcription factors of which the SXY-module is shared by both sets of genes. The SXY module is cooperatively bound by a multi-protein complex. Among them, the class II transactivator (CIITA) and NOD-, LRR- and CARD-containing 5 (NLRC5) play a major role in IFN-γ-induced MHC expression. In miPSC-CMs, IFN-γ-exposure induced both CIITA and NLRC5, resulting in MHC class I and II expression. This result suggests that the IFN-γ-CIITA and IFN-γ-NLRC5 axes promote MHC expression in miPSC-CMs. Together with the finding that CIITA and NLRC5 expression was not induced in miPSC-CMs during differentiation from immature miPSCs to miPSC-CMs, it is likely that the inhibitory pathway could constrain CIITA- and NLRC5-dependent transcriptional regulation of the MHC gene. Transcriptional activation of MHC genes also involves modulation of covalent histone modification and chromatin remodeling. Cell type-specific expression of MHC in differentiated miPSCs suggests that chromosomal re-modeling may take place during differentiation.

NKC activation against miPSC-CMs is mutually regulated by the characteristic expression of NKC ligands on miPSC-CMs including inhibitory ligands (such as MHC class I) and activating ligands (such as NKG2D and CD226). Lower expression of MHC class I molecules was also found in differentiated CMs derived from macaque iPSCs and embryonic stem (ES) cells. In vitro syngeneic co-culture experiments demonstrated that miPSC-CM lysis by NKCs was suppressed by IFN-γ-induced MHC class I expression. In contrast, through the activating ligands, mouse and human iPSC and ES cells were killed by NKCs. The lysis of mouse iPSC-CMs by syngeneic NKCs decreased in blocking experiments performed with anti-CD226 and anti-NKG2D antibodies. These effects of antibodies on miPSC-CM survival were independent of the expression of classical MHC class I, suggesting that inhibition of activating signals via CD226 and NKG2D were essential for miPSC-CMs to protect against NK attack. In addition to the direct interaction between miPSC-CMs and NKCs, miPSC-CM sheet culture supernatants contained high concentrations of SDF-1α/CXCL12 and MCP-1/CCL2, which stimulate the migration and cytotoxicity of NKCs, as determined by performing in vitro chemotaxis assays. Activated human NKCs have been found to migrate in response to known ligands for SDF-1α/CXCL12 and MCP-1/CCL2. In contrast, several studies reported the effects of MCP-1/CCL2 on resting NK cytoxicity. Thus, SDF-1α/CXCL12 may recruit NKCs to transplants and MCP-1/CCL2 may contribute to the activation of NKCs after transplantation.

The heterogeneity of mature mouse NKC can be represented by four subsets on the basis of CD27 and CD11b expression. NKC differentiation has been shown to proceed from CD27hi CD11blo to CD27hi CD11bhi and ultimately to CD27lo CD11bhi. The cytotoxic NKC subset is mainly CD27lo CD11bhi NKCs, and this subset accounts for more than 90% of NK cells from peripheral blood. In this study, we focused on NKC with a natural cytotoxicity receptor (NCR), such as CD335. CD335 is a natural cytotoxicity receptor (NCR) and represents a novel NK cell-specific molecule involved in NK cell activation that has been implicated in NK cell-mediated lysis of several autologous target cell types. We did not analyze NKC differentiation in transplanted mice by measuring CD27 and CD11b; however, we suspected that CD27hi CD11bhi NKCs may be major mediators of the NKC-related immune response after miPSC-CM transplantation. Further investigations would be required to determine the subset of NKCs that is responsible for this activity.

For clinical applications, CMs derived from MHC-homozygous iPSCs are supposed to be mostly transplanted to MHC-heterozygous recipients using banked iPSC lines from healthy donors. Although the induced expression of classical MHC class I on iPSC-CM may be an effective treatment for inhibiting cytolysis by NKCs after transplantation in syngeneic models, it remains unclear whether IFN-γ treatment of iPSC-CMs would suppress the cytotoxicity of NKCs in a homo-–hetero model. Following transplantation of iPSC-derived dopamine neurons, which weakly expressed MHC class I, NKC infiltration into transplants did not significantly differ between homo-–hetero MHC-matched and MHC-mismatched settings. However, the heterozygous MHC NKCs scarcely showed specific lysis to homozygous MHC iPSC-derived T cells and endothelial cells with significant MHC class I expression. Therefore, we suspect that IFN-γ treatment of iPSC-CMs may contribute to the suppression of NKCs even in a homo-–hetero setting, using human iPSCs.

The evaluation of engraftment by subcutaneous graft transplantation is a limitation of our study; however, previous studies reported that immunological responses to iPSC-CM after subcutaneous transplantation and
transplantation into cardiac tissues or surfaces were similar. This similarity was confirmed in both mouse and macaque models of iPSC-CM transplantation. Moreover, in our previous study, transplanted iPSC-CMs were similarly engrafted or rejected in these transplantation models in subcutaneous tissue as compared with cardiac

**Figure 4.** The cytotoxic effect of NKCs on iPSC-CMs *in vitro*. (A) The percentage of LDH release in supernatants of co-cultured iPSC-CMs and NKCs compared with that of 0.5% Triton X-treated controls; expressed as means ± SD (n = 3, respectively); **p < 0.001, *p < 0.05. (B) The percentage of fluorescence intensities of iPSC-CMs labeled with CAM compared with that of 0.5% Triton X-treated control; expressed as means ± SD (n = 3, respectively); **p < 0.0001, *p < 0.05. (C) Images of viable iPSC-CMs labeled with CAM after co-culture. Scale bar: 200 μm (D) The concentration of Granzyme B in the supernatants of co-cultures iPSC-CMs and NKCs; expressed as means ± SD (n = 3, respectively); **p < 0.0001, *p < 0.01.
Together with these findings, we believe that similar results in our study could be obtained if iPSC-CMs were transplanted into cardiac tissue.

In conclusion, the engraftment of miPSC-CMs after transplantation was impeded by innate immune responses, which were induced by NKC activation due to lower expression of MHC class I and the existence of activating ligands for CD226 and NKG2D on miPSC-CMs in the mouse syngeneic transplantation model.
Further studies are warranted to elucidate the optimal immunosuppressive treatment including NKC-related innate immune rejection for the clinical application of cell transplantation therapy using human iPSC-CMs.

Materials and Methods

All animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. The institutional Ethics Review Committee for Animal Experimentation of the Osaka University Graduate School of Medicine approved all experimental protocols.

Cell culture, cardiomyogenic differentiation, and sheet generation. We treated the 959A2-1 miPSC line (generated from C57BL/6 mouse embryonic fibroblasts) with neomycin to establish an miPSC line that stably expressed DsRed and luciferase (DsRed-Luciferase-miPSC), as previously described.26 DsRed-Luciferase-miPSCs were cultured in ESGRO complete PLUS Clonal Grade Medium (Merck Millipore). Cardiomyogenic differentiation was induced as previously reported,20,27,47 with slight modifications. To generate embryoid bodies (EBs), 3000 cells were resuspended in 100 μL aliquots of differentiation medium (DM; Dulbecco’s Modified Eagle’s Medium (DMEM; Nacalai Tesque) containing 15% fetal bovine serum (FBS; Biofill), 100 mM non-essential amino acids (NEAA; Invitrogen), 2 mM L-glutamine (Invitrogen), and 0.1 mM L-2-mercaptoethanol (Invitrogen)) containing 0.2 mM L-6-bromoindirubin-39-oxime (BIO; a glycogen synthase kinase-3b inhibitor, to activate the Wnt-signaling pathway) (Calbiochem), and cultured in 96-well Costar Ultra-Low attachment multiwell plates (Sigma–Aldrich) to activate the Wnt-signaling pathway. The effect of BIO was neutralized by adding an inhibitor of Wnt production (1WP-3) at 1 μM on day 3, and each EB was transferred to a flat-bottom plate for adhesion culture on day 5. On days 6, 10, and 14, culture medium was exchanged for serum-free Modified Eagle’s Medium (MEM; Invitrogen) with insulin transferrin-selenium-X (IT-SX) supplemented with 4 mM lactic acid (Wako Pure Chemical) for the purification of cardiomyocytes. On day 16, the cell clusters were dissociated. To eliminate undifferentiated iPSCs, SSEA-1-negative iPSC-CMs were isolated with an SH800Z cell sorter (Sony) and seeded on thermoresponsive dishes (2–2.5 × 10^6 CMs/well; Upcell; CellSeed), and incubated at 37 °C for 2 to 3 days. They were then transferred to 20 °C until the cells detached spontaneously to form scaffold-free cell sheets before transplantation was performed.

Transplantation of iPSC-CM sheets. Adult male C57BL/6 (6–9-weeks old, 22–27 g) were generally anesthetized via isoflurane inhalation, and the DsRed-Luciferase-miPSC-CM sheets were subcutaneously transplanted into the backs of mice.

In vivo depletion of NKC. An anti-NK1.1 (PK136) Ab and a control mouse IgG Ab were purchased from Bio X Cell and Sigma–Aldrich, respectively. mAbs were resuspended in phosphate-buffered saline (PBS). Recipient mice received 400 μg anti-NK1.1 mAb intraperitoneally (i.p.) on days −1, 1, 3, and 5 post-transplantation to deplete NKC in the mice.

Immunohistochemical staining and histological analysis. All primary antibodies used for immunohistochemical staining and histological analysis are listed in Table S1A. miPSC-CMs were fixed with 4% paraformaldehyde and labeled with primary antibodies such as anti-cardiac troponin T (Abcam) or anti-phallolidin (Life technologies) (Table S1A), followed by secondary antibodies such as Alexa Fluor 488- or Alexa Fluor 555-conjugated goat or donkey anti-mouse or anti-rabbit antibodies (ThermoFisher Scientific). Nuclei were counterstained with Hoechst 33342 (Dojindo). The cells were assessed using a confocal microscope (FLUOVIEW FV10i; Olympus).

Flow cytometry. All primary antibodies used for flow cytometry are listed in Table S1A. Cultured iPSC-CMs were dissociated with 0.25% trypsin-EDTA for 6 min at 37 °C and labeled with fluorescently conjugated antibodies against H2Db (Abcam), H2Kb (BioLegend), Qa1-b (Novus), Qa2 (Abcam), and SSEA-1 (BioLegend) for 30 min at 4 °C. Dissociated iPSC-CMs were labeled with antibodies against MULT-1 (R&D Systems), Rae-1 (R&D Systems), H60 (R&D Systems), CD112 (R&D Systems), or CD155 (R&D Systems), followed by fluorescein-conjugated secondary antibodies. iPSC-CMs were also labeled with antibodies against cardiac troponin T (BD Pharmingen) after fixation using BD Cytofix Fixation Buffer (Becton Dickinson), followed by incubation with fluorescein-conjugated secondary antibodies. Spleens were harvested from C57BL/6 mice and homogenized, followed by suspension in PBS. The suspended homogenate was then filtered with a 40-μm nylon filter (Corning), centrifuged, and incubated with red blood cell lysing buffer (Santa Cruz) for 3 min at room temperature.
temperature to lyse the red blood cells. After centrifugation, the splenocytes were washed and labeled with fluorescently conjugated antibodies against CD335 (BioLegend), NK1.1 (BioLegend), and CD107a (BioLegend) for 30 min at 4 °C and analyzed using a FACSCanto II flow cytometer (Becton Dickinson). Splenocytes were labeled with antibodies against Granzyme B (BioLegend) after fixation and permeabilization using Fixp3/Transcription Factor Staining Buffer Set (Thermo Fisher Scientific). Samples were assessed using the FACSCanto II system (Becton Dickinson), and data were analyzed using Diva software (Becton Dickinson).

Luciferase assay and BLI. To evaluate the quantity of transplanted iPSC-CMs, BLI was performed using the IVIS Lumina II instrument (PerkinElmer), as previously described, and the luminescence intensities of the iPSC-CMs were measured. Five minutes before measuring luminescence, RediJect D-Luciferin Ultra Bioluminescence Substrate (PerkinElmer) was injected intraperitoneally (150 mg/kg body weight). The integration time was fixed at 8 min for each image. All images were analyzed with Living Image Software (PerkinElmer).

LDH-release assay. After splenocytes derived from C57BL/6 were obtained as described above, NKCs were isolated from splenocytes by magnetic-activated cell sorting using negative-selection kits (NK Cell Isolation Kit II, Miltenyi Biotec) and cultured using ALy5505NK-EX medium (Cell, Science & Technology Institute Inc.) with 1000 U/ml mouse IL-2 (BioLegend) for two weeks. iPSC-CMs were treated with 100 ng/ml IFN-γ (R&D Systems) for 48 h. LDH-release assays were performed using an LDH Cytotoxicity Detection Kit (Takara Bio). Cultured NKCs were washed and incubated with blocking antibodies against DNAM-1 (CD226) (Thermo Fisher Scientific) and NKG2D (BioLegend) for 90 min at room temperature. After washing, NKCs were cocultured with iPSC-CMs in a 96-well plate for 6 h. After incubation in the dark for 30 min at room temperature, the absorbance at 490 nm was recorded with a microplate reader (DS Pharma Biomedical), with a reference wavelength of 600 nm. The experiments were performed in triplicate. LDH release was determined as the percentage of LDH released compared with that of the 0.5% Triton X-treated control.

Cell viability assay. Cell viability of iPSC-CMs after co-culture with NKGs was analyzed using the Terascan VP system (Minerva Tech), as described previously. iPSC-CMs were labeled with CAM (Dojindo) diluted from a 1 mM stock solution in dimethyl sulfoxide for 30 min at 37 °C. The labeled cells were then incubated with NKGs for 4 h. Cells were then washed twice in Dulbecco’s modified Eagle’s medium (DMEM) and adjusted to 2 × 10^4 cells/ml in DMEM supplemented with 10% FBS. CAM-labeled IPS-CMs and NKCs incubated with neutralizing antibodies (prepared as described above) were cocultured in a 96-well half-area plate (Costar) and incubated in the dark for 30 min at 37 °C. The fluorescence intensity was measured before and after the 4-h culture, and the specific cell viability was calculated as the percentage of fluorescence intensity compared with that of the 0.5% Triton X-treated control.

Chemokine and Granzyme B measurements. The iPSC-CM sheet culture supernatants were collected and analyzed by performing immunoassays based on fluorescently labeled microspheres to measure chemokine production with the Bio-Plex suspension array system (Bio-Rad). Granzyme B levels were measured in the co-culture supernatants of iPSC-CMs and NKCs using a Mouse Granzyme B Coated ELISA Kit (Thermo Fisher Scientific), according to the manufacturer’s protocol.

Real-time polymerase chain reaction (PCR) experiments. Total RNA was extracted using an RNeasy Kit (Qiagen), and cDNA was synthesized using a SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). Real-time PCR was performed on a Viia7 real-time PCR system (Thermo Fisher Scientific), using TaqMan PCR master mix. The following genes were analyzed using TaqMan gene expression assays (Thermo Fisher Scientific): Ciita (Mm00482914_m1) and Nlrc5 (Mm01243039_m1). Relative gene-expression levels were calculated using the Ct method, with normalization to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression (Mm00868322_m1).

NKC migration assay. NKCs were labeled with CAM (Dojindo, Kumamoto) as described above. After incubation with blocking antibodies against SDF-1α/CXCL12 (Abcam) and MCP-1/CCL2 (Abcam) for 90 min at room temperature, the iPSC-CM sheet culture supernatants were placed in the bottom wells of a Transwell migration plate (Costar Corning). CAM-labeled NKCs were added to the upper wells, and plates were incubated for 90 min at 37 °C to allow the cells to migrate. The fluorescence intensity was recorded with a microplate reader (DS Pharma Biomedical) with an excitation wavelength of 490 nm and an emission wavelength of 520 nm. Experiments were performed in triplicate. The migrated cells were quantified by measuring the fluorescence intensity of the bottom wells, and the chemotaxis of NKCs was calculated as the percentage of the fluorescence intensity compared with that of the control well, in which NKCs were added to the bottom wells.

Transplantation of IFN-γ-treated iPSC-CMs and administration of an antibody cocktail including CD226- and NKG2D-blocking antibodies. iPSC-CMs were treated with 100 ng/ml IFN-γ while generating iPSC-CM sheets on thermoresponsive dishes (2–2.5 × 10^5 cells/ml; Upcell; CellSeed). Mice were administered blocking antibodies against CD226 (Thermo Fisher Scientific) and NKG2D (BioLegend), or control mouse and hamster IgG Abs (Sigma–Aldrich and BioLegend). mAbs were resuspended in PBS. Recipient mice received 100 μg anti-CD226 mAb and 100 μg anti-NKG2D mAb i.p. on days –1, 1, 3, and 5 days post-transplantation to suppress NKCs in mice.

Semi-quantitative scoring of the number of CD335-positive cells in the grafts. CD335-positive cells in the grafts were counted in the fluorescently stained samples. The numbers of CD335-positive cells were...
automatically counted with a BZ-X700 microscope (KEYENCE) and its installed software, using at least 5 randomly selected views for each sample. The results are expressed as the mean ± standard deviation (SD) for each mouse.

**Statistical analysis.** Continuous variables are reported as the mean ± SD and were compared using Student’s t-test or one-way analysis of variance with Tukey’s honestly significant difference test. P-values < 0.05 were considered statistically significant. All statistical analyses were performed using JMP Pro software, version 13.0 (SAS).

**Data Availability**

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

**References**

1. Towbin, J. A. & Bowles, N. E. The failing heart. *Nature* **415**, 227–233 (2002).
2. Jessup, M. & Brozena, S. Heart failure. *N. Engl. J. Med.* **348**, 2007–2018 (2003).
3. Yoshida, Y. & Yamanaka, S. Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell-based regeneration. *Circulation* **122**, 80–87 (2010).
4. Yoshida, Y. & Yamanaka, S. iPS cells: a source of cardiac regeneration. *J. Mol. Cell Cardiol* **50**, 327–332 (2011).
5. Miki, K. et al. Bioengineered myocardium derived from induced pluripotent stem cells improves cardiac function and attenuates cardiac remodeling following chronic myocardial infarction in rats. *Stem Cells Transl Med* **1**, 430–437 (2012).
6. Hyguchi, T. et al. Functional and electrical integration of induced pluripotent stem cell-derived cardiomyocytes in a myocardial infarction rat heart. *Cell Transplant* **24**, 2479–2489 (2015).
7. Kawamura, M. et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. *Circulation* **126**, S29–S37 (2012).
8. Kawamura, T. et al. Cardiomyocytes Derived from HLA-Genotypically Allogeneic Pluripotent Stem Cells Exhibit Reduced Allogeneic Immune Sanctuary in HLA-Matched Non-human Primates. *Stem Cell Reports* **6**, 312–320 (2016).
9. Mizukami, Y. et al. HLA-matched induced pluripotent stem cells can attenuate cellular and humoral immune responses but are still susceptible to innate immunity in pigs. *PLoS One* **9**, e98319 (2014).
10. Braciale, T. J. Antigen processing for presentation by MHC class I molecules. *Carr. Opin. Immunol.* **4**, 59–62 (1992).
11. Pazmany, L. et al. Protection from natural killer cell-mediated lysis by HLA-A expression on target cells. *Science* **274**, 792–795 (1996).
12. Bix, M. et al. Rejection of class I HLA-deficient haemopoitetic cells by irradiated MHC-matched mice. *Nature* **349**, 329–331 (1991).
13. Liao, N. S. et al. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. *Science* **253**, 199–202 (1991).
14. Karre, K. Natural killer cell recognition of missing self. *Nat Immunol* **9**, 477–480 (2008).
15. Shibuya, A. et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. *Immunology* **44**, 573–581 (1996).
16. Bottino, C. et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. *J Exp Med* **198**, 557–567 (2003).
17. Houchins, J. P., Yabe, T., McSherry, C. & Bach, F. H. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. *J Exp Med* **173**, 1017–1020 (1991).
18. Carapito, R. & Bahram, S. Genetics, genomics, and evolutionary biology of NKG2D ligands. *Immunol Rev* **267**, 88–116 (2015).
19. Koch, J., Steinek, A., Watzl, C. & Mandelboim, O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. *Trends Immunol* **34**, 182–191 (2013).
20. Kawamura, A. et al. Teratocarcinomas Arising from Allogeneic Induced Pluripotent Stem Cell-Derived Cardiac Tissue Constructs Provoked Host Immune Reaction in Mice. *Sci Rep* **6**, 19466 (2016).
21. Robertson, M. J. et al. Regulation of human natural killer cell migration and proliferation by the extracellular subfamily of CC chemokines. *Cell Immunol* **199**, 8–14 (2000).
22. Sugita, S. et al. Lack of T Cell Response to iPSC-Derived Retinal Pigment Epithelial Cells from HLA Homozygous Donors. *Stem Cell Reports* **7**, 619–634 (2016).
23. Rusche, H. et al. NK Cell Allolreactivity against KIR-Ligand-Mismatched HLA-Haplodidentical Tissue Derived from HLA Haplo-type Homozygous iPSCs. *Stem Cell Reports* **9**, 853–867 (2017).
24. Frenzel, L. P. et al. Role of natural-killer group 2 member D ligands and intercellular adhesion molecule 1 in natural killer cell-mediated lysis of murine embryonic stem cells and embryonic stem cell-derived cardiomyocytes. *Stem Cells* **27**, 307–316 (2009).
25. Kobayashi, K. S. & van den Elsen, P. J. NLRC5: a key regulator of MHC class I-dependent immune responses. *Nat Rev Immunol* **12**, 813–820 (2012).
26. van den Elsen, P. J. Expression regulation of major histocompatibility complex class I and class II encoding genes. *Front Immunol* **2**, 48 (2011).
27. Choi, N. M., Majumder, P. & Boss, J. M. Regulation of major histocompatibility complex class II genes. *Carr. Opin Immunol* **23**, 81–87 (2011).
28. Robbins, G. R. et al. Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins. *J Biol Chem* **287**, 24294–24303 (2012).
29. Meissner, T. B. et al. NLRC5 cooperates with the RXF transcription factor complex to induce MHC class I gene expression. *J Immunol* **188**, 4951–4958 (2012).
30. Dressel, R. et al. The tumorgenicity of mouse embryonic stem cells and *in vitro* differentiated neuronal cells is controlled by the recipient’s immune response. *PLoS One* **3**, e2662 (2008).
31. Dressel, R. et al. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. *FASEB J* **24**, 2164–2177 (2010).
32. Kruse, V. et al. Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partially Mediated by the Activating NK Receptor DNAM-1. *PLoS One* **10**, e0125544 (2015).
33. Gröschel, C. et al. Efficient Killing of Murine Pluripotent Stem Cells by Natural Killer (NK) Cells Requires Activation by Cytokines and Partially Depends on the Activating NK Receptor NKG2D. *Front Immunol* **8**, 870 (2017).
34. Robertson, M. J. Role of chemokines in the biology of natural killer cells. *J Leukoc Biol* **71**, 173–183 (2002).
35. Campbell, J. et al. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7. 1. *J Cell Biol* **141**, 1053–1059 (1998).
36. Campbell, J. et al. Unique subpopulations of CD36+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. *J Immunol* **166**, 6477–6482 (2001).
37. Inngjerdingen, M., Damaj, B. & Maghazachi, A. A. Expression and regulation of chemokine receptors in human natural killer cells. *Blood* **97**, 367–375 (2001).
38. Taub, D. D., Sayers, T. J., Carter, C. R. & Ortaldo, J. R. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. *J Immunol* **155**, 3877–3888 (1995).
39. Taub, D. D. *et al.* Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. *J Leukoc Biol* **59**, 81–89 (1996).
40. Maghazachi, A. A., Al-Aoukaty, A. & Schall, T. J. CC chemokines induce the generation of killer cells from CD56+ cells. *Eur J Immunol* **26**, 315–319 (2012).
41. Chiassone, L. *et al.* Maturation of mouse NK cells is a 4-stage developmental program. *Blood* **113**, 5488–96 (2009).
42. Fu, B. *et al.* Subsets of human natural killer cells and their regulatory effects. *Immunology* **141**, 483–489 (2014).
43. Sivori, S. *et al.* p46, a novel natural killer cell-specific surface molecule that mediates cell activation. *J Exp Med* **186**, 1129–1136 (1997).
44. Sivori, S. *et al.* Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. *J Leukoc Biol* **59**, 81–89 (1996).
45. Okita, K. *et al.* A more efficient method to generate integration-free human iPSC cells. *Nat Methods* **8**, 409–412 (2011).
46. Morizane, A. *et al.* MHC matching improves engraftment of iPSC-derived neurons in non-human primates. *Nat Commun* **8**, 385 (2017).
47. Naito, A. T. *et al.* Developmental stage-specific biphasic roles of Wnt/beta-catenin signaling in cardiomyogenesis and hematopoiesis. *Proc Natl Acad Sci USA* **103**, 19812–19817 (2006).
48. Kawamura, T. *et al.* N-glycans: phenotypic homology and structural differences between myocardial cells and induced pluripotent stem cell-derived cardiomyocytes. *PLoS One* **9**, e110164 (2014).
49. Yoshimura, M. *et al.* Identification of a novel HLA-A02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. *Oncol Rep* **32**, 33–39 (2014).

Acknowledgements
We thank Seiko Eiraku and Akima Harada for providing technical support. This study was supported by the Japan Science and Technology Agency as a part of the project entitled “Center for the Development of Myocardial Regenerative Treatments Using iPS Cells”.

Author Contributions
Y.N. provided the study materials, collected and/or assembled the data, and wrote the manuscript; S.Y., S.S., and K.T. analyzed and interpreted the data; S.M. and T.T. conceived and designed the study, collected and/or assembled the data, and wrote the manuscript; Y.S. conceived and designed the study and obtained financial support.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47134-3.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019